Culture for health and well-being. On culture’s potential contribution to the economy of well-being

The potential health benefits of culture receive increasing academic and policy attention. However, although new researchs on the links between culture and health and well-being are published regularly, it remains difficult to identify existing patterns of evidence and gaps. The CultureForHealth consortium was tasked by the European Commission with the role ofproviding a summary of such patterns, and to make policy recommendations as to how the European Union can build on existing knowledge, advance it, and support cultural and other relevant actors to guarantee that the health benefits of culture are recognised and unleashed. Doing so can support broader efforts to build what the OECD describes as an economyof well-being (2019

Culture for health and well-being. On culture’s potential contribution to the economy of well-being

The potential health benefits of culture receive increasing academic and policy attention. However, although new researchs on the links between culture and health and well-being are published regularly, it remains difficult to identify existing patterns of evidence and gaps. The CultureForHealth consortium was tasked by the European Commission with the role ofproviding a summary of such patterns, and to make policy recommendations as to how the European Union can build on existing knowledge, advance it, and support cultural and other relevant actors to guarantee that the health benefits of culture are recognised and unleashed. Doing so can support broader efforts to build what the OECD describes as an economyof well-being (2019

New approach for the treatment of pneumococcal diseases

Pneumolysin (PLY) is a proven virulence factor of Streptococcus pneumoniae, deeply involved in the development of pneumococcal invasive diseases. The antibacterial and adjunctive therapies currently used in the management of pneumococcal infection do not address the pneumolysin-induced cytotoxicity. Therefore, even if patients survive the infection, they may suffer from long-term disabilities as a consequence of the exposure to the toxin. This research seeks to address this problem by developing new approaches to the treatment of pneumococcal diseases, based on peptides or small molecules that target pneumolysin and inhibit its activity. The peptides and small molecules were evaluated for their capacity to inhibit the haemolytic activity of pneumolysin in vitro. In total, four peptides and six small molecules were selected for in vivo tests. In vivo experiments were performed using a pneumonia model, where each animal was administered PBS or peptide / small molecule in PBS intranasally, every 6 hours after intranasal infection. One peptide (P1) and three small molecules (SM6, SM10 and SM14) improved significantly the outcome of the treatment group over the control group, when looking at the CFU in the blood, disease sign score and survival comparison. Moreover, two small molecules (SM10 and SM14) tested ex vivo, showed the capacity to abolish pneumolysin cytotoxic effect on the ciliary function of rat ependymal cells. The pneumolysin inhibitors identified in this work were pointed as potential candidates to further testing in drug discovery